Evidence that selenium binding protein 1 is a tumor suppressor in prostate cancer

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Ansong, Emmanuel ^a   Ying, Qi ^a,b,c   Ekoue, Dede N ^a   Deaton, Ryan ^a   Hall, Andrew R ^a   Kajdacsy Balla, Andre ^a   Yang, Wancai ^a,c   Gann, Peter H ^a   Diamond, Alan M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NANJING AGRICULTURAL UNIVERSITY   (China)

^c XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; FLUOROURACIL; GLUTATHIONE PEROXIDASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; SELENIUM BINDING PROTEIN; SELENIUM BINDING PROTEIN 1; THIOREDOXIN REDUCTASE 1; UNCLASSIFIED DRUG; SELENBP1 PROTEIN, HUMAN; TUMOR MARKER;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER RECURRENCE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DRUG SENSITIVITY; FLUORESCENCE IMAGING; GLEASON SCORE; HCT116 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; CELL PROLIFERATION; HCT 116 CELL LINE; METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

BIOMARKERS, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; GENES, TUMOR SUPPRESSOR; HCT116 CELLS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SELENIUM-BINDING PROTEINS; TISSUE ARRAY ANALYSIS;

EID: 84930678808     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127295     Document Type: Article

References (35)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socio-economic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236. doi: 10.3322/caac.20121 PMID: 21685461
2. Fitzpatrick JM (2008) Management of localized prostate cancer in senior adults: the crucial role of comorbidity. BJU Int 101 Suppl 2: 16-22. doi: 10.1111/j.1464-410X.2007.07487.x PMID: 18307688
3. Nguyen CT, Kattan MW (2012) Formalized prediction of clinically significant prostate cancer: is it possible? Asian J Androl 14: 349-354. doi: 10.1038/aja.2011.140 PMID: 22367181
4. Bansal MP, Oborn CJ, Danielson KG, Medina D (1989) Evidence for two selenium-binding proteins distinct from glutathione peroxidase in mouse liver. Carcinogenesis 10: 541-546. PMID: 2924398
5. Porat A, Sagiv Y, Elazar Z (2000) A 56-kDa selenium-binding protein participates in intra-Golgi protein transport. J Biol Chem 275: 14457-14465. PMID: 10799528
6. Jeong JY, Zhou JR, Gao C, Feldman L, Sytkowski AJ (2014) Human selenium binding protein-1 (hSP56) is a negative regulator of HIF-1alpha and suppresses the malignant characteristics of prostate cancer cells. BMB Rep 47: 411-416. PMID: 24874852
7. Jeong JY, Wang Y, Sytkowski AJ (2009) Human selenium binding protein-1 (hSP56) interacts with VDU1 in a selenium-dependent manner. Biochem Biophys Res Commun 379: 583-588. doi: 10.1016/j.bbrc.2008.12.110 PMID: 19118533
8. Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, et al. (2004) Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 202: 321-329. PMID: 14991897
9. Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, et al. (2006) Selenium binding protein 1 in ovarian cancer. Int J Cancer 118: 2433-2440. PMID: 16380993
10. Kim H, Kang HJ, You KT, Kim SH, Lee KY, Kim TI, et al. (2006) Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 6: 3466-3476. PMID: 16645984
11. Li T, Yang W, Li M, Byun DS, Tong C, Nasser S, et al. (2008) Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res 52: 1289-1299. doi: 10.1002/mnfr.200700331 PMID: 18435490
12. Huang C, Ding G, Gu C, Zhou J, Kuang M, Ji Y, et al. (2012) Decreased Selenium-Binding Protein 1 Enhances Glutathione Peroxidase 1 Activity and Downregulates HIF-1alpha to Promote Hepatocellular Carcinoma Invasiveness. Clin Cancer Res 18: 3042-3053. doi: 10.1158/1078-0432.CCR-12-0183 PMID: 22512980
13. Yang M, Sytkowski AJ (1998) Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res 58: 3150-3153. PMID: 9679983
14. Melamed J, Datta MW, Becich MJ, Orenstein JM, Dhir R, Silver S, et al. (2004) The cooperative prostate cancer tissue resource: a specimen and data resource for cancer researchers. Clin Cancer Res 10: 4614-4621. PMID: 15269132
15. Kajdacsy-Balla A, Geynisman JM, Macias V, Setty S, Nanaji NM, Berman JJ, et al. (2007) Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol 38: 113-121. PMID: 17318343
16. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27: 3459-3464. doi: 10.1200/JCO.2008.20.4669 PMID: 19433685
17. Fang W, Goldberg ML, Pohl NM, Bi X, Tong C, Xiong B, et al. (2010) Functional and physical interaction between the selenium-binding protein 1 (SBP1) and the glutathione peroxidase 1 selenoprotein. Carcinogenesis 31: 1360-1366. doi: 10.1093/carcin/bgq114 PMID: 20530237
18. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, et al. (2009) Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28: 2796-2805. doi: 10.1038/onc.2009.139 PMID: 19483725
19. Pohl NM, Tong C, Fang W, Bi X, Li T, Yang W (2009) Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts. PLoS One 4: e7774. doi: 10.1371/journal.pone.0007774 PMID: 19924303
20. Davis CD, Tsuji PA, Milner JA (2012) Selenoproteins and Cancer Prevention. Annu Rev Nutr 32: 73-95. doi: 10.1146/annurev-nutr-071811-150740 PMID: 22404120
21. Wohlhueter RM, McIvor RS, Plagemann PG (1980) Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 104: 309-319. PMID: 7419607
22. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338. PMID: 12724731
23. Kaeser MD, Pebernard S, Iggo RD (2004) Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem 279: 7598-7605. PMID: 14665630
24. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269. PMID: 10430607
25. Zhang XP, Liu F, Wang W (2011) Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci U S A 108: 8990-8995. doi: 10.1073/pnas.1100600108 PMID: 21576488
26. Ansong E, Yang W, Diamond AM (2014) Molecular cross-talk between members of distinct families of selenium containing proteins. Mol Nutr Food Res 58: 117-123. doi: 10.1002/mnfr.201300543 PMID: 24395536
27. Jerome-Morais A, Wright ME, Liu R, Yang W, Jackson MI, Combs GF Jr, et al. (2012) Inverse association between glutathione peroxidase activity and both selenium-binding protein 1 levels and Gleason score in human prostate tissue. Prostate 72: 1006-1012. doi: 10.1002/pros.21506 PMID: 22072582
28. Loughery J, Cox M, Smith LM, Meek DW (2014) Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Nucleic Acids Res 42: 7666-7680. doi: 10.1093/nar/gku501 PMID: 24928858
29. Carroll AG, Voeller HJ, Sugars L, Gelmann EP (1993) p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23: 123-134. PMID: 8104329
30. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. (1994) WAF1/ CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174. PMID: 8118801
31. Lee SH, Nam JK, Park JK, Lee JH, Min do S, Kuh HJ (2014) Differential protein expression and novel biomarkers related to 5-FU resistance in a 3D colorectal adenocarcinoma model. Oncol Rep 32: 1427-1434. doi: 10.3892/or.2014.3337 PMID: 25050539
32. Geybels MS, van den Brandt PA, Schouten LJ, van Schooten FJ, van Breda SG, Rayman MP, et al. (2014) Selenoprotein gene variants, toenail selenium levels, and risk for advanced prostate cancer. J Natl Cancer Inst 106: dju003. doi: 10.1093/jnci/dju003 PMID: 24563517
33. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama 306: 1549-1556. doi: 10.1001/jama.2011.1437 PMID: 21990298
34. Zhuo P, Diamond AM (2009) Molecular mechanisms by which selenoproteins affect cancer risk and progression. Biochim Biophys Acta 115: 227-242.
35. Rayman MP (2009) Selenoproteins and human health: insights from epidemiological data. Biochim Biophys Acta 1790: 1533-1540. doi: 10.1016/j.bbagen.2009.03.014 PMID: 19327385